|
1
|
Lemos TJDS, Silva HGDS, Previato JO, Mendonça-Previato L, Freitas EOD, Barbosa AS, Franzolin MR, Santos LFD, Melo BDS, Anjos GFD, Gonçalves RHN, Domingos MDO. O26 Polysaccharides as Key Players in Enteropathogenic E. coli Immune Evasion and Vaccine Development. Int J Mol Sci 2024; 25:2878. [PMID: 38474124 DOI: 10.3390/ijms25052878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Revised: 02/23/2024] [Accepted: 02/23/2024] [Indexed: 03/14/2024] Open
Abstract
Enteropathogenic Escherichia coli (EPEC) produce a capsule of polysaccharides identical to those composing the O-antigen polysaccharide of its LPS (lipopolysaccharide) molecules. In light of this, the impact of O26 polysaccharides on the immune evasion mechanisms of capsulated O26 EPEC compared to non-capsulated enterohemorrhagic Escherichia coli (EHEC) was investigated. Our findings reveal that there was no significant difference between the levels in EPEC and EHEC of rhamnose (2.8:2.5), a molecule considered to be a PAMP (Pathogen Associated Molecular Patterns). However, the levels of glucose (10:1.69), heptose (3.6:0.89) and N-acetylglucosamine (4.5:2.10), were significantly higher in EPEC than EHEC, respectively. It was also observed that the presence of a capsule in EPEC inhibited the deposition of C3b on the bacterial surface and protected the pathogen against lysis by the complement system. In addition, the presence of a capsule also protected EPEC against phagocytosis by macrophages. However, the immune evasion provided by the capsule was overcome in the presence of anti-O26 polysaccharide antibodies, and additionally, these antibodies were able to inhibit O26 EPEC adhesion to human epithelial cells. Finally, the results indicate that O26 polysaccharides can generate an effective humoral immune response, making them promising antigens for the development of a vaccine against capsulated O26 E. coli.
Collapse
Affiliation(s)
| | | | - José Osvaldo Previato
- Instituto de Biofísica Carlos Chagas Filho, UFRJ, Avenida Carlos Chagas Filho, 373, Cidade Universitária, Rio de Janeiro 21941-902, RJ, Brazil
| | - Lucia Mendonça-Previato
- Instituto de Biofísica Carlos Chagas Filho, UFRJ, Avenida Carlos Chagas Filho, 373, Cidade Universitária, Rio de Janeiro 21941-902, RJ, Brazil
| | - Elisangela Oliveira de Freitas
- Instituto de Biofísica Carlos Chagas Filho, UFRJ, Avenida Carlos Chagas Filho, 373, Cidade Universitária, Rio de Janeiro 21941-902, RJ, Brazil
| | - Angela Silva Barbosa
- Laboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, Brazil
| | - Marcia Regina Franzolin
- Laboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, Brazil
| | - Luis Fernando Dos Santos
- Centro de Bacteriologia, Núcleo de Doenças Entéricas, Instituto Adolfo Lutz, Avenida Dr. Arnaldo, 355, São Paulo 01246-000, SP, Brazil
| | - Bruna de Sousa Melo
- Laboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, Brazil
| | - Geovana Ferreira Dos Anjos
- Laboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, Brazil
| | | | - Marta de Oliveira Domingos
- Laboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, Brazil
| |
Collapse
|
|
2
|
Coelho FF, da Silva MA, Lopes TB, Polatto JM, de Castro NS, Andrade LAF, Lourenço KL, Sato HI, de Carvalho AF, Coelho HP, Bagno FF, Luz D, Viala VL, Cattony PQ, Melo BDS, Moro AM, Quintilio W, Barbosa AP, Bomfim CG, Soares CP, Guzzo CR, Fonseca FG, Durigon EL, Gazzinelli RT, Ribeiro Teixeira SM, Piazza RMF, Fernandes AP. SARS-CoV-2 Rapid Antigen Test Based on a New Anti-Nucleocapsid Protein Monoclonal Antibody: Development and Real-Time Validation. Microorganisms 2023; 11:2422. [PMID: 37894080 PMCID: PMC10608853 DOI: 10.3390/microorganisms11102422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 08/27/2023] [Accepted: 09/01/2023] [Indexed: 10/29/2023] Open
Abstract
SARS-CoV-2 diagnostic tests have become an important tool for pandemic control. Among the alternatives for COVID-19 diagnosis, antigen rapid diagnostic tests (Ag-RDT) are very convenient and widely used. However, as SARS-CoV-2 variants may continuously emerge, the replacement of tests and reagents may be required to maintain the sensitivity of Ag-RDTs. Here, we describe the development and validation of an Ag-RDT during an outbreak of the Omicron variant, including the characterization of a new monoclonal antibody (anti-DTC-N 1B3 mAb) that recognizes the Nucleocapsid protein (N). The anti-DTC-N 1B3 mAb recognized the sequence TFPPTEPKKDKKK located at the C-terminus of the N protein of main SARS-CoV-2 variants of concern. Accordingly, the Ag-RDT prototypes using the anti-DTC-N 1B3 mAB detected all the SARS-CoV-2 variants-Wuhan, Alpha, Gamma, Delta, P2 and Omicron. The performance of the best prototype (sensitivity of 95.2% for samples with Ct ≤ 25; specificity of 98.3% and overall accuracy of 85.0%) met the WHO recommendations. Moreover, results from a patients' follow-up study indicated that, if performed within the first three days after onset of symptoms, the Ag-RDT displayed 100% sensitivity. Thus, the new mAb and the Ag-RDT developed herein may constitute alternative tools for COVID-19 point-of-care diagnosis and epidemiological surveillance.
Collapse
Affiliation(s)
- Fabiana Fioravante Coelho
- Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil;
- Hospital da Polícia Militar de Minas Gerais, Polícia Militar de Minas Gerais, Belo Horizonte 30110-013, Brazil
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Miriam Aparecida da Silva
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Thiciany Blener Lopes
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Juliana Moutinho Polatto
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Natália Salazar de Castro
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Luis Adan Flores Andrade
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Karine Lima Lourenço
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Hugo Itaru Sato
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Alex Fiorini de Carvalho
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Helena Perez Coelho
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Flávia Fonseca Bagno
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Daniela Luz
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Vincent Louis Viala
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Pedro Queiroz Cattony
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Bruna de Sousa Melo
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Ana Maria Moro
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Wagner Quintilio
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Ana Paula Barbosa
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Camila Gasque Bomfim
- Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-900, Brazil; (C.G.B.); (C.P.S.); (C.R.G.); (E.L.D.)
| | - Camila Pereira Soares
- Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-900, Brazil; (C.G.B.); (C.P.S.); (C.R.G.); (E.L.D.)
| | - Cristiane Rodrigues Guzzo
- Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-900, Brazil; (C.G.B.); (C.P.S.); (C.R.G.); (E.L.D.)
| | - Flavio Guimarães Fonseca
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Edison Luiz Durigon
- Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-900, Brazil; (C.G.B.); (C.P.S.); (C.R.G.); (E.L.D.)
| | - Ricardo Tostes Gazzinelli
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Santuza M. Ribeiro Teixeira
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| | - Roxane Maria Fontes Piazza
- Instituto Butantan, São Paulo 05503-900, Brazil; (M.A.d.S.); (J.M.P.); (D.L.); (V.L.V.); (P.Q.C.); (B.d.S.M.); (A.M.M.); (W.Q.); (A.P.B.); (R.M.F.P.)
| | - Ana Paula Fernandes
- Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil;
- Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Belo Horizonte 31310-260, Brazil; (T.B.L.); (N.S.d.C.); (L.A.F.A.); (K.L.L.); (H.I.S.); (A.F.d.C.); (H.P.C.); (F.F.B.); (F.G.F.); (R.T.G.); (S.M.R.T.)
| |
Collapse
|
|
3
|
de Sousa Melo B, Fernandes BHV, Lopes-Ferreira MVA, Henrique C, Piazza RMF, Luz D. Zebrafish embryo sensitivity test as in vivo platform to anti-Shiga toxin compound screening. Braz J Microbiol 2020; 51:1021-1027. [PMID: 32449119 DOI: 10.1007/s42770-020-00305-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Accepted: 05/18/2020] [Indexed: 10/24/2022] Open
Abstract
Shiga toxin-producing Escherichia coli (STEC) pathotype secretes two types of AB5 cytotoxins (Stx1 and Stx2), responsible for complications such as hemorrhagic colitis (HC) and hemolytic uremic syndrome (HUS) in infected patients, which could lead to sequels and death. Currently, there is no effective treatment against the cytotoxic effect of these toxins. However, in order to approve any therapy molecule, an animal experiment is required in order to evaluate the efficacy and safety of therapeutic approaches. The use of alternative small host models is growing among human infectious disease studies, particularly the vertebrate zebrafish model, since relevant results have been described for pathogen-host interaction. In this sense, the present work aimed to analyze the toxic effect of Shiga toxins in zebrafish embryo model in order to standardize this method in the future to be used as a fast, simple, and efficient methodology for the screening of therapeutic molecules. Herein, we demonstrated that the embryos were sensitive in a dose-dependent manner to both Stx toxins, with LD50 of 22 μg/mL for Stx1 and 33 μg/mL for Stx2, and the use of anti-Stx polyclonal antibody abolished the toxic effect. Therefore, this methodology can be a rapid alternative method for selecting promising compounds against Stx toxins, such as recombinant antibodies.
Collapse
Affiliation(s)
| | - Bianca Helena Ventura Fernandes
- Laboratório de Controle Genético e Sanitário Animal, Unidade Zebrafish, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | | | - Camila Henrique
- Laboratório de Bacteriologia, Instituto Butantan, São Paulo, Brazil
| | | | - Daniela Luz
- Laboratório de Bacteriologia, Instituto Butantan, São Paulo, Brazil. .,Laboratório de Monoclonais, Instituto de Ciência e Tecnologia, Universidade Federal de São Paulo, Rua Talim, 330, São José dos Campos, SP, 12231-280, Brazil.
| |
Collapse
|